Clinical Commander

Back to dossier
cardio.cardiogenic-shock.takotsubo-lvot-obstruction.v1PRODUCTION
cardio.cardiogenic-shock.takotsubo-lvot-obstruction.v1

Cardiogenic shock — Takotsubo with dynamic LVOT obstruction (SAM-mediated)

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm Takotsubo with LVOT obstruction and shock — apical ballooning + basal hyperkinesis + LVOT gradient ≥30 mmHg + SAM + shock physiology; this is a SUB-variant of takotsubo CS with INVERTED management physiology

Inputs
2
Actions
0
Advance rule
Set
Advance when

LVOT-obstruction Takotsubo confirmed + shock overlay documented

Patient inputs (13)

Mandatory rule-out of obstructive CAD per Ghadri 2018 InterTAK criteria; LV gram confirms apical ballooning

Postmenopausal female ~90% predominant; informs risk-stratification anchor

InterTAK registry — ~90% female, ~80% age >50; LVOT-subtype rate within Takotsubo ~15–25% (Templin NEJM 2015 PMID 26332547)

Tachycardia worsens LVOT obstruction (less diastolic filling time → smaller LV cavity → worse gradient); esmolol-titration gate

End-organ damage marker; renal function gates DOAC dosing for mural-thrombus prophylaxis

Trigger identification — physical-stressor Takotsubo has higher mortality (Templin NEJM 2015)

Modest rise typical Takotsubo discordance; helps confirm diagnosis (vs MI mimic)

Markedly elevated; LVOT obstruction adds volume/pressure load → BNP often disproportionately high

LVOT pulsed/continuous Doppler — gradient ≥30 mmHg at rest OR ≥50 mmHg with provocation defines obstructive variant; SAM of MV on 2D; posteriorly directed MR jet on color

Diffuse T-wave inversion + QT prolongation typical; rule out STEMI mimic; QT often >500 ms (torsades risk)

Hypotension severity gates fluid + phenylephrine titration; SBP often paradoxically WORSE with inotropes — diagnostic clue

SCAI 2022 staging + LVOT-subtype response: lactate often improves rapidly with subtype-appropriate therapy (fluids + phenylephrine + esmolol), worsens with inotrope error

TEE preferred over TTE if window suboptimal — definitive for SAM, MR mechanism, and gradient localization

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateninginotrope_error_worsening_lvot_gradient
    Patient with Takotsubo CS deteriorating after dobutamine/milrinone/NE initiation (paradoxical BP drop + rising lactate + new harsh systolic murmur) — DIAGNOSTIC clue to occult LVOT obstruction; STOP inotropes IMMEDIATELY and switch to phenylephrine + esmolol + fluids
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningiabp_error_worsening_lvot_obstruction
    Patient with Takotsubo CS deteriorating after IABP placement (afterload reduction worsens dynamic obstruction) — REMOVE IABP IMMEDIATELY; same mechanism that makes IABP CONTRAINDICATED in HOCM
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningrefractory_mr_with_shock_in_lvot_subtype
    Severe MR (posteriorly directed jet from SAM) with refractory hemodynamic collapse despite optimal phenylephrine + esmolol + fluid bundle — consider rare cardiothoracic surgical mitral intervention
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_takotsubo_with_lvot_obstruction_pattern
    Recurrent Takotsubo episode with same LVOT-obstruction pattern (gradient ≥30 mmHg + SAM) — anatomic predisposition (basal septal bulge or sigmoid septum); requires CONTINUED long-term β-blocker (not just transient acute treatment)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremural_thrombus_from_apical_akinesia_in_lvot_subtype
    LV apical thrombus on echo OR severe apical akinesia + EF <35 in LVOT-subtype Takotsubo — initiate AC × 3 mo; risk peaks while LV remains dysfunctional
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Takotsubo CS with dynamic LVOT obstruction — INVERTED physiology bundle: PRELOAD-DEPENDENT + AFTERLOAD-RESPONSIVE; fluids + pure α-pressor + β-blocker; AVOID inotropes/IABP/diuretics/nitrates
axis: takotsubo_lvot_obstruction_cs_phenotype
Selected axis "Takotsubo CS with dynamic LVOT obstruction — INVERTED physiology bundle: PRELOAD-DEPENDENT + AFTERLOAD-RESPONSIVE; fluids + pure α-pressor + β-blocker; AVOID inotropes/IABP/diuretics/nitrates" by default fallback (first axis)
  • phenylephrine
    first line
    vasopressor_pure_alpha
    40–360 µg/min IV (titrate to MAP ≥65 and falling LVOT gradient) • IV • continuous
    triggers: takotsubo_lvot_obstruction_subtype_with_shock, sbp_lt_90_with_dynamic_lvot_gradient
    Pure α-agonist raises afterload without inotropy → reduces dynamic LVOT gradient; ESC HFA 2016 Lyon position is the definitive source; mechanistic parallel to HOCM acute management
    rxcui 8163
  • esmolol
    first line
    short_acting_beta_blocker
    500 µg/kg IV bolus → 50–200 µg/kg/min infusion • IV • continuous, titrate to HR 60–80 and gradient resolution
    triggers: takotsubo_lvot_obstruction_subtype, dynamic_lvot_gradient_at_or_above_30_mmhg, sam_with_mr_on_echo
    β1-blocker reduces septal hyperkinesis and slows HR → larger LV cavity + reduced gradient; esmolol short-acting allows rapid titration; this is the one Takotsubo subset where β-blocker is the right answer (vs general AVOID rule)
    rxcui 49737
  • isotonic crystalloid (LR or NS)
    first line
    isotonic_crystalloid
    250–500 mL bolus, repeat until gradient drops or pulmonary edema • IV • reassess after each bolus with serial echo
    triggers: takotsubo_lvot_obstruction_subtype, preload_dependent_physiology, no_pulmonary_edema_yet
    Increased preload enlarges LV cavity → reduces dynamic gradient; CONTRAINDICATED in non-LVOT Takotsubo with pulmonary edema; clinical clue: BP improves with each bolus in LVOT-subtype
    rxcui 4337
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg daily; INR target 2–3 • PO • daily × 3 mo
    triggers: ef_lt_35_with_apical_akinesia, lv_thrombus_on_echo
    AHA 2022 Class IIa for LV thrombus (extrapolated to apical-ballooning Takotsubo); 3-mo course typically sufficient given recovery timeline
    rxcui 11289
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg BID (or 2.5 mg BID per dose-reduction criteria) • PO • BID × 3 mo for mural thrombus prophylaxis
    triggers: warfarin_intolerant_or_inr_compliance_concern, apical_akinesia_with_severe_lv_dysfunction
    Off-label-but-rational DOAC alternative for LV thrombus prophylaxis in Takotsubo recovery
    rxcui 1364430
  • carvedilol
    add on
    beta_blocker_nonselective_alpha1
    3.125 mg BID after LVOT gradient resolves and patient off IV esmolol • PO • BID, titrate
    triggers: lvot_subtype_recovery_phase, transition_from_iv_esmolol_to_oral_bb
    Long-term β-blocker more reasonable in LVOT-subtype Takotsubo than general Takotsubo; theoretical recurrence-prevention rationale per Lyon 2016 ESC HFA position
    rxcui 20352
  • metoprolol succinate
    add on
    beta_blocker_selective_b1
    25 mg daily, titrate to 100 mg daily • PO • daily
    triggers: lvot_subtype_recovery_phase_alternative_bb, carvedilol_intolerant
    Alternative oral β-blocker for LVOT-subtype Takotsubo recovery maintenance per Lyon 2016 ESC HFA position
    rxcui 6918

outpatient playbook — drug actions (2)

  1. 1. continue carvedilol or metoprolol succinate long-term
    maintenance dose • PO • BID/daily
    trigger: LVOT-subtype Takotsubo recovery
    Recurrence-prevention rationale per Lyon 2016 ESC HFA position; more reasonable in LVOT subtype than general Takotsubo
  2. 2. discontinue warfarin / apixaban at 3 mo if EF recovered + apical akinesia resolved
    taper / stop per AHA 2022 LV thrombus consensus • PO • n/a
    trigger: Normalized echo at 3 mo
    Mural thrombus risk resolves with LV recovery

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Bedside echo: apical ballooning + basal hyperkinesis + LVOT gradient ≥30 mmHg at rest (or ≥50 mmHg with provocation) + SAM of mitral valve — Takotsubo with dynamic LVOT obstruction; TTE/TEE: systolic anterior motion of anterior mitral leaflet + posteriorly directed MR jet in patient with confirmed Takotsubo apical ballooning; Patient with Takotsubo CS deteriorating paradoxically after inotrope/IABP initiation (drop in BP + rising lactate) — diagnostic clue to occult LVOT obstruction; OBTAIN STAT echo with Doppler.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — Takotsubo with dynamic LVOT obstruction (SAM-mediated)** (cardio.cardiogenic-shock.takotsubo-lvot-obstruction.v1).
Scope: Confirm Takotsubo with LVOT obstruction and shock — apical ballooning + basal hyperkinesis + LVOT gradient ≥30 mmHg + SAM + shock physiology; this is a SUB-variant of takotsubo CS with INVERTED management physiology

No severity triggers fired against current inputs.

Plan

Regimen axis: **Takotsubo CS with dynamic LVOT obstruction — INVERTED physiology bundle: PRELOAD-DEPENDENT + AFTERLOAD-RESPONSIVE; fluids + pure α-pressor + β-blocker; AVOID inotropes/IABP/diuretics/nitrates**.
1. phenylephrine 40–360 µg/min IV (titrate to MAP ≥65 and falling LVOT gradient) IV continuous (vasopressor_pure_alpha, first line) — Pure α-agonist raises afterload without inotropy → reduces dynamic LVOT gradient; ESC HFA 2016 Lyon position is the definitive source; mechanistic parallel to HOCM acute management
2. esmolol 500 µg/kg IV bolus → 50–200 µg/kg/min infusion IV continuous, titrate to HR 60–80 and gradient resolution (short_acting_beta_blocker, first line) — β1-blocker reduces septal hyperkinesis and slows HR → larger LV cavity + reduced gradient; esmolol short-acting allows rapid titration; this is the one Takotsubo subset where β-blocker is the right answer (vs general AVOID rule)
3. isotonic crystalloid (LR or NS) 250–500 mL bolus, repeat until gradient drops or pulmonary edema IV reassess after each bolus with serial echo (isotonic_crystalloid, first line) — Increased preload enlarges LV cavity → reduces dynamic gradient; CONTRAINDICATED in non-LVOT Takotsubo with pulmonary edema; clinical clue: BP improves with each bolus in LVOT-subtype
4. warfarin 5 mg daily; INR target 2–3 PO daily × 3 mo (vitamin_k_antagonist, comorbidity specific) — AHA 2022 Class IIa for LV thrombus (extrapolated to apical-ballooning Takotsubo); 3-mo course typically sufficient given recovery timeline
5. apixaban 5 mg BID (or 2.5 mg BID per dose-reduction criteria) PO BID × 3 mo for mural thrombus prophylaxis (doac_factor_xa_direct, comorbidity specific) — Off-label-but-rational DOAC alternative for LV thrombus prophylaxis in Takotsubo recovery
6. carvedilol 3.125 mg BID after LVOT gradient resolves and patient off IV esmolol PO BID, titrate (beta_blocker_nonselective_alpha1, add on) — Long-term β-blocker more reasonable in LVOT-subtype Takotsubo than general Takotsubo; theoretical recurrence-prevention rationale per Lyon 2016 ESC HFA position
7. metoprolol succinate 25 mg daily, titrate to 100 mg daily PO daily (beta_blocker_selective_b1, add on) — Alternative oral β-blocker for LVOT-subtype Takotsubo recovery maintenance per Lyon 2016 ESC HFA position

Setting playbook (outpatient) — 2–4 week recovery echo — confirm complete LV recovery + gradient resolution; discontinue mural-thrombus AC at 3 mo if EF normalized + apical akinesia resolved; CONTINUE β-blocker long-term in LVOT-subtype (recurrence-prevention rationale); psych follow-up + recurrence education
8. continue carvedilol or metoprolol succinate long-term maintenance dose PO BID/daily — LVOT-subtype Takotsubo recovery (Recurrence-prevention rationale per Lyon 2016 ESC HFA position; more reasonable in LVOT subtype than general Takotsubo)
9. discontinue warfarin / apixaban at 3 mo if EF recovered + apical akinesia resolved taper / stop per AHA 2022 LV thrombus consensus PO n/a — Normalized echo at 3 mo (Mural thrombus risk resolves with LV recovery)

Non-pharmacologic actions:
- Recurrence education — ~5–10% over follow-up per Templin NEJM 2015 PMID 26332547; LVOT-subtype recurrence risk
- Stressor mitigation counseling (psych referral if not already engaged)
- Cardiac rehab if persistent LV dysfunction

AVOID / contraindication checks:
- Inotropes_AVOID_in_takotsubo_lvot_obstruction (dobutamine/milrinone/NE — worsen septal hyperkinesis and gradient; ESC HFA 2016 Lyon position; mechanistic parallel to HOCM where inotropes are CONTRAINDICATED)
- Diuretics_AVOID_in_takotsubo_lvot_obstruction (preload reduction → smaller LV cavity → worse gradient — pulmonary edema management requires inotrope free strategy: phenylephrine + cautious afterload up + gradient reduction first)
- Nitrates_AVOID_in_takotsubo_lvot_obstruction (preload + afterload reduction → worse gradient; nitroglycerin/nitroprusside CONTRAINDICATED)
- IABP_AVOID_in_takotsubo_lvot_obstruction (afterload reduction → worse dynamic obstruction; same reasoning that makes IABP CONTRAINDICATED in HOCM)
- NE_AVOID_or_use_only_with_phenylephrine_failure (NE has β1 inotropy that worsens gradient; if used, must combine with esmolol to block β1 effect)
- Impella_use_with_caution (LV unloading may worsen gradient; case reports mixed; reserve for refractory after fluids/phenylephrine/esmolol fail)
- Beta_blocker_REQUIRED_in_lvot_subtype (paradoxical to general Takotsubo AVOID rule; esmolol IV acutely → carvedilol/metoprolol succinate orally for maintenance)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015) — rapid clearance with subtype-appropriate therapy
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q12h with LVOT gradient measurement (recovery faster than non-LVOT Takotsubo — gradient resolves within 1–2 wks)
- telemetry continuous with qt monitoring (torsades risk from QT prolongation; check K + Mg)
- ecg at admission then q24h (T-wave inversion evolution)
- esmolol drip titration to HR 60-80 (lower HR reduces gradient)

Setting (outpatient) monitoring:
- Symptom check at 6 mo and 12 mo
- Repeat echo with LVOT Doppler at 6 mo (confirm gradient resolution sustained)

Follow-up plan: Repeat echo at 1–4 wks to confirm complete LVOT gradient resolution + LV recovery (faster than non-LVOT Takotsubo); psych follow-up; long-term β-blocker (carvedilol/metoprolol succinate) is more reasonable in this subset given LVOT-recurrence risk than in general Takotsubo (Lyon 2016 ESC HFA position favors continued β-blocker in LVOT-subtype recovery); recurrence ~5–10% over follow-up
- Close-out criterion: Recovery echo + psych follow-up booked + β-blocker maintenance plan documented

Monitoring phase: A-line, central line, lactate clearance, urine output, telemetry (QT prolongation + torsades watch), SERIAL ECHO q12h with LVOT gradient measurement (recovery is faster than non-LVOT subtype — gradient resolves within 1–2 wks as apical akinesis recovers)

Disposition

Current setting: outpatient — 2–4 week recovery echo — confirm complete LV recovery + gradient resolution; discontinue mural-thrombus AC at 3 mo if EF normalized + apical akinesia resolved; CONTINUE β-blocker long-term in LVOT-subtype (recurrence-prevention rationale); psych follow-up + recurrence education

Disposition criteria:
- Complete recovery (EF ≥55 + symptom-free + AC discontinued) → routine surveillance with continued β-blocker maintenance

Escalation triggers (move to higher acuity):
- Recurrent Takotsubo episode → ED + repeat full workup including LVOT Doppler + reinforced stressor management
- Persistent symptoms despite normal echo → cardiac MRI for occult dysfunction or HOCM mimic

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Patient with Takotsubo CS deteriorating after dobutamine/milrinone/NE initiation (paradoxical BP drop + rising lactate + new harsh systolic murmur) — DIAGNOSTIC clue to occult LVOT obstruction; STOP inotropes IMMEDIATELY and switch to phenylephrine + esmolol + fluids
- [LIFE_THREATENING] Patient with Takotsubo CS deteriorating after IABP placement (afterload reduction worsens dynamic obstruction) — REMOVE IABP IMMEDIATELY; same mechanism that makes IABP CONTRAINDICATED in HOCM
- [LIFE_THREATENING] Severe MR (posteriorly directed jet from SAM) with refractory hemodynamic collapse despite optimal phenylephrine + esmolol + fluid bundle — consider rare cardiothoracic surgical mitral intervention

Citations

- Lyon 2016 ESC HFA position statement on Takotsubo (definitive source for LVOT-subtype management); InterTAK consortium / Ghadri 2018 Eur Heart J expert consensus Part I + II; Templin NEJM 2015 PMID 26332547 (InterTAK registry); ACC/AHA 2022 HF Guideline; HOCM literature (Maron AHA 2020) for mechanistic LVOT obstruction parallel [PMID:26332547](https://pubmed.ncbi.nlm.nih.gov/26332547/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)
- Cited evidence (PMID 20200382) [PMID:20200382](https://pubmed.ncbi.nlm.nih.gov/20200382/)
- Cited evidence (PMID 33704937) [PMID:33704937](https://pubmed.ncbi.nlm.nih.gov/33704937/)
- Cited evidence (PMID 37634145) [PMID:37634145](https://pubmed.ncbi.nlm.nih.gov/37634145/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Lyon 2016 ESC HFA position statement on Takotsubo (definitive source for LVOT-subtype management); InterTAK consortium / Ghadri 2018 Eur Heart J expert consensus Part I + II; Templin NEJM 2015 PMID 26332547 (InterTAK registry); ACC/AHA 2022 HF Guideline; HOCM literature (Maron AHA 2020) for mechanistic LVOT obstruction parallel — PMID:26332547
  • Cited evidence (PMID 35718438) — PMID:35718438
  • Cited evidence (PMID 20200382) — PMID:20200382
  • Cited evidence (PMID 33704937) — PMID:33704937
  • Cited evidence (PMID 37634145) — PMID:37634145